IP Library Granted Patent US 7,105,493
Granted Patent B2
US 7,105,493 · App. 10/602,694 · Granted Sep 12, 2006

Methods and compositions for treating flaviviruses and pestiviruses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,105,493
App. No.
10/602,694
Granted
Sep 12, 2006
Kind
B2
Abstract

A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Claims (18)

1. A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering to said host an anti-virally effective amount of a β-D-2′-methyl-ribofuranosyl nucleoside or a pharmaceutically acceptable salt or ester thereof.

2. The method of claim 1 , wherein the nucleoside is a pyrimidine nucleoside.

3. The method of claim 1 , wherein the nucleoside is a purine nucleoside.

4. The method of claim 1 wherein the β-D-2′-methyl-ribofuranosyl nucleoside is administered in combination or alternation with a second anti-flavivirus or anti-pestivirus agent.

5. The method of claim 4 , wherein the second anti-flavivirus or anti-pestivirus agent is selected from the group consisting of interferon, ribavirin, a protease inhibitor, a thiazolidine derivative, a polymerase inhibitor, and a helicase inhibitor.

6. The method of claim 5 , wherein the second anti-flavivirus or anti-pestivirus agent is interferon.

7. The method of claim 5 , wherein the second anti-flavivirus or anti-pestivirus agent is ribavirin.

8. The method of claim 1 , wherein the compound is in the form of a dosage unit.

9. The method of claim 8 , wherein the dosage unit contains 50 to 1000 mg of the β-D-2′methyl-ribofuranosyl nucleoside.

10. The method of claim 8 , wherein said dosage unit is a tablet or capsule.

11. The method of claim 1 , wherein the host is a human.

12. The method of claim 1 , wherein the β-D-2′-methyl-ribofuranosyl nucleoside is in substantially pure form.

13. The method of claim 12 , wherein the β-D-2′-methyl-ribofuranosyl nucleoside is at least 90% by weight of the β-D-isomer.

14. The method of claim 12 , wherein the β-D-2′-methyl-ribofuranosyl nucleoside is at least 95% by weight of the β-D-isomer.

15. The method of claim 1 , wherein the flavivirus or pestivirus is a Dengue virus.

16. The method of claim 1 , wherein the flavivirus or pestivirus is a West Nile virus.

17. The method of claim 1 , wherein the flavivirus or pestivirus is a yellow fever virus.

18. The method of claim 1 , wherein the flavivirus or pestivirus is a bovine viral diarrhea virus (BVDV).

Assignments (1)
CHANGE OF NAME Recorded Sep 24, 2018
From: IDENIX PHARMACEUTICALS, INC.
To: IDENIX PHARMACEUTICALS LLC
Reel/Frame 047149/0206 →